Pharma Mar, S.A. (BME:PHM)

Market Cap	1.50B -6.2%
Revenue (ttm)	221.39M +26.6%
Net Income	74.99M +187.0%
EPS	4.30 +188.6%
Shares Out	17.36M
PE Ratio	20.12
Forward PE	34.12
Dividend	0.80 (0.92%)
Ex-Dividend Date	Jun 25, 2025

Volume	54,493
Average Volume	52,564
Open	87.20
Previous Close	86.50
Day's Range	84.10 - 87.75
52-Week Range	65.00 - 102.40
Beta	0.45
RSI	58.03
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.